Go Pro
→ MILLIONAIRE MASTERCLASS INVITE: Altucher (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.85
-1.4%		$3.69
$7.96
▼
$24.15
$14.37M0.6315,685 shs58,621 shs
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.71
$4.41
$1.35
▼
$50.10
$3.66M1.04227,964 shsN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
$4.26
+1.3%		$4.64
$3.29
▼
$20.00
$13.70M1.465,793 shs14,411 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.81
-0.1%		$0.97
$0.74
▼
$12.23
$13.63M-1.73988,549 shs2.26 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.34%-7.37%-28.47%-39.16%-50.00%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%0.00%
Passage Bio, Inc. stock logo
PASG
Passage Bio
-6.67%-12.50%-5.41%-10.26%-48.34%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-3.38%-5.16%-23.23%-26.05%-92.06%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AlloVir, Inc. stock logo
ALVR
AlloVir
$2.85
-1.4%		$3.69
$7.96
▼
$24.15
$14.37M0.6315,685 shs58,621 shs
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$1.71
$4.41
$1.35
▼
$50.10
$3.66M1.04227,964 shsN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
$4.26
+1.3%		$4.64
$3.29
▼
$20.00
$13.70M1.465,793 shs14,411 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$0.81
-0.1%		$0.97
$0.74
▼
$12.23
$13.63M-1.73988,549 shs2.26 million shs
Options Trading Made Easy - Download Now Cover
Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AlloVir, Inc. stock logo
ALVR
AlloVir
-0.34%-7.37%-28.47%-39.16%-50.00%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%0.00%
Passage Bio, Inc. stock logo
PASG
Passage Bio
-6.67%-12.50%-5.41%-10.26%-48.34%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-3.38%-5.16%-23.23%-26.05%-92.06%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AlloVir, Inc. stock logo
ALVR
AlloVir
0.00
N/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00
N/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
2.11
Hold$13.25211.40% Upside
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.50
ReduceN/AN/A

Current Analyst Ratings Breakdown

Latest APTO, ALVR, PASG, and TPST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
7/13/2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/A$29.35 per shareN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/A$5.90 per shareN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AlloVir, Inc. stock logo
ALVR
AlloVir
-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$45.52M-$11.32N/AN/AN/AN/A-218.59%-72.93%11/9/2026 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$26.26M-$4.28N/AN/AN/AN/A-576.56%-134.99%11/4/2026 (Estimated)

Latest APTO, ALVR, PASG, and TPST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$0.30-$0.34-$0.04-$0.34N/AN/A
8/10/2026Q2 2026
Passage Bio, Inc. stock logo
PASG
Passage Bio
-$2.44-$2.44N/A-$2.44N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AlloVir, Inc. stock logo
ALVR
AlloVir
N/AN/AN/AN/AN/A
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AlloVir, Inc. stock logo
ALVR
AlloVir
N/A
86.78
86.78
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
Passage Bio, Inc. stock logo
PASG
Passage Bio
N/A
1.22
1.22
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
0.38
0.38

Institutional Ownership

CompanyInstitutional Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
66.05%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Passage Bio, Inc. stock logo
PASG
Passage Bio
53.48%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
AlloVir, Inc. stock logo
ALVR
AlloVir
32.07%
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.33%
Passage Bio, Inc. stock logo
PASG
Passage Bio
4.90%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
36.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
AlloVir, Inc. stock logo
ALVR
AlloVir
1105.04 million3.43 millionNo Data
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
Passage Bio, Inc. stock logo
PASG
Passage Bio
1303.22 million3.06 millionNo Data
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
416.89 million10.78 millionNo Data

Recent News About These Companies

Tempest Therapeutics consensus price target decreased by 36.36% to $7.14
October 2 at 7:53 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/tempest-therapeutics-consensus-price-target-decreased-by-36-36-to-7-14/ar-AA2dnCAC
Tempest signs related-party R&D pact, reshapes leadership
September 29 at 6:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31063518
HC Wainwright Analysts Raise Earnings Estimates for TPST
September 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31056304
Tempest Therapeutics names Nancy Freda-Smith to its board
September 23, 2026  |  streetinsider.comhttps://www.streetinsider.com/Board+Changes/Tempest+Therapeutics+names+Nancy+Freda-Smith+to+its+board/27093511.html
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367428/0/en/tempest-appoints-global-finance-leader-nancy-freda-smith-to-board-of-directors.html
Tempest Therapeutics (NASDAQ:TPST) Trading Down 20.1% - Here's What Happened
September 22, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31037831
Tempest Therapeutics: Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 16, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-09/69591841-tempest-therapeutics-tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform-399.htm
Tempest Stock Exploded on a CAR-T Option Most Investors Had Never Heard Of
September 16, 2026  |  moneymorning.comM
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
September 16, 2026  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/09/61809066/why-tempest-therapeutics-shares-are-trading-higher-by-around-50-here-are-20-stocks-moving-premarket?utm_source=snapi
Tempest Gets Option To License CD7-Targeted In Vivo CAR-T Platform; Overnight Stock Surge 64%
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691311/tempest-gets-option-to-license-cd7-targeted-in-vivo-car-t-platform-overnight-stock-surge-64.aspx
Tempest Therapeutics options CD7 lentiviral CAR-T platform from Senlang
September 16, 2026  |  streetinsider.comhttps://www.streetinsider.com/Corporate+News/Tempest+Therapeutics+options+CD7+lentiviral+CAR-T+platform+from+Senlang/27064842.html
Tempest Therapeutics Gains Option to License New In-Body CAR-T Technology From Senlang
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/tempest-therapeutics-gains-option-license-214530532.html
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
September 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/15/3362637/0/en/tempest-secures-exclusive-option-to-license-clinical-stage-cd7-targeted-lentiviral-in-vivo-car-t-platform.html
Tempest Therapeutics announces $2.5M private placement
September 11, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/tempest-therapeutics-announces-25m-private-placement/ar-AA2c1rwV
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
September 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/11/3360287/0/en/tempest-therapeutics-announces-up-to-7-5-million-private-placement.html
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
September 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/08/3357654/0/en/tempest-to-present-at-the-h-c-wainwright-28th-annual-global-investment-conference.html
Tempest Therapeutics Announces Senlang Collaboration to Advance TPST-4003 In Vivo CAR-T Pipeline and Appoints Two New Directors
August 13, 2026  |  quiverquant.comQ
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344974/0/en/tempest-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Tempest Therapeutics: Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T
July 21, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69081647-tempest-therapeutics-tempest-announces-development-collaboration-with-senlang-biotechnology-for-tpst-4003-a-cd7-targeted-next-generation-in-vivo-car-399.htm
Tempest Therapeutics Announces Strategic Partnership with Senlang to Advance TPST-4003 into First-in-Human Study in Autoimmune Diseases
July 21, 2026  |  quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

AlloVir stock logo

AlloVir NASDAQ:ALVR

$2.85 -0.04 (-1.38%)
As of 10/1/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Passage Bio stock logo

Passage Bio NASDAQ:PASG

$4.26 +0.06 (+1.31%)
As of 03:38 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$0.80 0.00 (-0.14%)
As of 03:43 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas